BioSight
Companies
Design Therapeutics, Inc. logo

DSGN

NASDAQCARLSBAD, CA
Design Therapeutics, Inc.

Design Therapeutics develops small-molecule drug candidates using its platform technology to target genetic diseases caused by transcriptional dysregulation. The company is focused on Friedrich ataxia, with its lead program DT-216P2 in clinical development. Design Therapeutics is in the early-to-mid stage of development, actively conducting clinical trials and nonclinical studies for its candidates.

Price history not yet available for DSGN.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar